CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., February 6, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., December 14, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor...
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination – – Luvelta was generally well-tolerated – – Data supports...
65th American Society of Hematology Annual Meeting and Exposition – Poster
Anti-leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBFA2T3::GLIS2 AML Presenter & Primary Author: Dr. Soheil Meshinch
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
SOUTH SAN FRANCISCO, Calif., December 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Piper Sandler 35th Annual Healthcare Conference – Presentation
ESMO Congress 2023 – Presentation
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
- Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression – - Safety profile was consistent with prior data in...
14th Annual World ADC Conference – Presentations and Poster
Development of Next Generation ADCs Using Novel Expression Platforms & Precise ConjugationPresenter: Gang YinDiscovery of Novel Linker Payloads for Site-Specific ADCs with Improved Efficacy & Therapeutic IndexPresenter: Krishna BajjuriPrecision Engineering for...
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., October 16, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five...
